share_log

Lake Street Maintains Buy on Evogene, Lowers Price Target to $12

Benzinga ·  Aug 23 21:56  · Ratings

Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $30 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment